Localized
Localized
Advertisement
Rafael Sanchez-Salas, MDLocalized | January 21, 2025
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
View More
Rafael Sanchez-Salas, MDLocalized | January 21, 2025
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Jihad Kaouk, MDLocalized | January 21, 2025
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Ian Thompson, Jr., MDLocalized | January 21, 2025
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Akhil Abraham Saji, MDLocalized | January 2, 2025
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Emily MenendezLocalized | November 4, 2024
GETUG 14 recruited patients with both intermediate- and high-risk PCa, randomizing them to receive RT or stADT plus RT.
Marc Greenstein, DOmCSPC | October 31, 2024
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Emily MenendezLocalized | September 24, 2024
Patients were guided through a VR experience to view their specific anatomy in a 3-dimensional space.
Katy MarshallLocalized | July 29, 2024
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
Emily MenendezLocalized | June 26, 2024
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Michael D. Stifelman, MDLocalized | June 17, 2024
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Christopher Wallis, MD, PhD, FRCSCLocalized | June 3, 2024
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Zachary BessetteLocalized | May 31, 2024
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Emily MenendezLocalized | May 10, 2024
Prostate cancer is the 2nd most diagnosed cancer among men worldwide, but the disease lacks established re-treatment options.
Advertisement
Advertisement
Advertisement